News

Neurocrine's INGREZZA Achieves Remarkable Success in TD Treatment

Neurocrine's INGREZZA Achieves Remarkable Success in TD Treatment

INGREZZA Demonstrates Efficacy in Treating Tardive Dyskinesia

SAN DIEGO - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has announced impressive results from a recent study illustrating that nearly 60% of participants experienced remission of tardive dyskinesia after a 48-week treatment with INGREZZA (valbenazine) capsules. This revelation stems from the KINECT-4 study, a pivotal long-term clinical trial dedicated to addressing this debilitating movement disorder.

Understanding Tardive Dyskinesia and Study Details

Tardive dyskinesia (TD) manifests as involuntary, repetitive motions, often triggered by prolonged use of specific antipsychotic drugs. The KINECT-4 Phase 3 study involved 163 individuals with moderate to severe TD, who received INGREZZA for the entirety of the 48 weeks. The primary goal of the study was to evaluate changes in the Abnormal Involuntary Movement Scale (AIMS) score, a tool used to assess the severity of TD symptoms.

Study Outcomes and Remission Rates

The findings revealed that 59.2% of participants achieved a score of 1 or below on every AIMS item by Week 48, indicating a remission of symptoms. When looking at dosage, 65.0% of those on the 40 mg dose successfully reached remission compared to 57.8% in the 80 mg group. Notably, 10% of participants demonstrated complete resolution of symptoms with an AIMS total score of 0.

Safety and Tolerability Observations

In addition to evaluating efficacy, the study included thorough monitoring of INGREZZA’s safety and tolerability. Treatment-emergent adverse events (TEAEs) occurring in more than 5% of participants included headaches and urinary tract infections. Other parameters, such as psychiatric stability and vital signs, remained relatively stable and were not deemed clinically significant.

Delving into Recent Developments at Neurocrine

Recently, Neurocrine Biosciences shared more data at the 2024 Psych Congress in Boston, which included findings regarding INGREZZA's benefits for patients with dysphagia and improvements in their quality of life post-treatment. INGREZZA functions as a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, receiving FDA approval for use in adults suffering from tardive dyskinesia and chorea linked with Huntington's disease.

Financial Performance and Future Aspirations

Neurocrine Biosciences is gaining attention alongside notable positive news. The company’s recent earnings report for the third quarter of 2024 displayed substantial growth, with sales of INGREZZA reaching $613 million. This significant performance has led to an upward revision of their annual revenue guidance to between $2.3 and $2.32 billion, indicating a 25% increase compared to the previous year.

Market Predictions and Analyst Ratings

BMO Capital Markets has adjusted its price target for Neurocrine Biosciences from $114 to $121, maintaining a Market Perform rating based on encouraging third-quarter outcomes and expectations surrounding the potential FDA approval for crinecerfont, which targets congenital adrenal hyperplasia (CAH). This medication holds considerable promise with the potential to generate peak revenues around $600 million.

Investments in Growth and Innovation

CEO Kyle Gano revealed a strategic $300 million share repurchase plan, signifying the company’s commitment to nurturing revenue growth. Alongside this, Neurocrine is preparing for the rollout of Crinecerfont, aiming at pediatric and community endocrinology practices, thus broadening its market outreach.

Research and Future Prospects

Neurocrine is actively investing in novel research and development initiatives, progressing its pipeline with Phase III trials for NBI-845 and NBI-568 expected in 2025. This steady evolution highlights the company's dedication to expanding their therapeutic offerings.

Frequently Asked Questions

What is INGREZZA used for?

INGREZZA is a medication used to treat tardive dyskinesia and chorea associated with Huntington’s disease.

What were the remission rates observed in the KINECT-4 study?

The study found that approximately 59.2% of participants achieved remission after 48 weeks of treatment.

What percentage of participants achieved complete resolution of symptoms?

10% of participants demonstrated a complete resolution of tardive dyskinesia symptoms with a total AIMS score of 0.

How has Neurocrine's financial performance been recently?

Neurocrine reported strong growth, with INGREZZA sales reaching $613 million, and raised its annual revenue guidance significantly.

What future developments are expected from Neurocrine?

Neurocrine is anticipating launching new treatments such as crinecerfont and advancing its research pipeline with upcoming studies.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 255

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 266

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 176

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 210

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 113

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 251

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 115

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 59

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Scent Dispensing Solution for Hunting Enthusiasts

Updated Category News Views 168

Introducing a Game-Changing Scent Dispensing System In the world of hunting, attracting game animals can often be a challenge. A new invention, designed specifically for this purpose, promises to make the process much simpler and more efficient. The inventor of this innovative scent dispensing system, THE DRAG LINE PRO, envisioned a better way to utilize a scent drag...

Continue Reading
Corby Spirit and Wine Limited Reports Impressive Fiscal Results

Updated Category News Views 295

Corby Spirit and Wine Limited Announces Strong Fiscal Performance Corby Spirit and Wine Limited, renowned for its position as a leading Canadian manufacturer, marketer, and importer of spirits, has recently unveiled impressive results for its fourth quarter and full-year fiscal 2025. The company demonstrated significant growth in revenue, achieving total revenues of...

Continue Reading
Sezzle Faces Setback as Short-Seller Targets Its Practices

Updated Category News Views 113

Sezzle's Stock Takes a Dramatic Hit Recently, the buy now, pay later (BNPL) provider Sezzle experienced a significant decrease in its stock value. Reports indicate that shares fell over 28.6% in early trading after Hindenburg Research disclosed a short position against the company due to concerns surrounding risky lending practices. Understanding the Short-Selling...

Continue Reading
Exploring the Growth of $1000 in Marsh & McLennan Cos Today

Updated Category News Views 116

Understanding Long-Term Investment in Marsh & McLennan Marsh & McLennan Cos (NYSE: MMC) has established itself as a financial powerhouse, outperforming the market consistently over the past two decades. Investors have experienced an impressive annualized return of 13.31%, showcasing the benefits of long-term investment strategies. The Value of Persistence in Investing...

Continue Reading
Discover Toll Brothers' Latest Luxury Homes at Overbrook Estates

Updated Category News Views 671

Introducing Overbrook Estates by Toll Brothers Toll Brothers, Inc. (NYSE:TOL), a renowned name in luxury homebuilding, excitedly unveils its newest community: Overbrook Estates. This anticipated project is set to grace the Huntersville area, offering homebuyers elegant living in a master-planned environment. Positioned conveniently off Highway 77, this prime location sets...

Continue Reading